Jarisch–Herxheimer reaction

From Wikipedia, the free encyclopedia
  (Redirected from Herxheimer reaction)
Jump to: navigation, search
Herxheimer reaction
Classification and external resources
ICD-10 T78.2
ICD-9-CM 995.0
DiseasesDB 32939

A Jarisch–Herxheimer reaction (English: /ˌjɑːrɪʃ ˈhɛərkshmər/) is a reaction to endotoxin-like products released by the death of harmful microorganisms within the body during antibiotic treatment. Efficacious antimicrobial therapy results in lysis (destruction) of bacterial cell membranes, and in the consequent release into the bloodstream of bacterial toxins, resulting in a systemic inflammatory response.

Jarisch–Herxheimer reactions are usually not life-threatening.

Signs and symptoms[edit]

It resembles bacterial sepsis and can occur after initiation of antibacterials, such as mild silver protein, penicillin or tetracycline, for the treatment of louse-borne relapsing fever (80–90% of patients) and in tick-borne relapsing fever (30–40%). It usually manifests within a few hours of the first dose of antibiotic as fever, chills, rigor, hypotension, headache, tachycardia, hyperventilation, vasodilation with flushing, myalgia (muscle pain), exacerbation of skin lesions and anxiety. The intensity of the reaction indicates the severity of inflammation. Reaction commonly occurs within two hours of drug administration, but is usually self-limiting. It is observed in 50% of patients with primary syphilis and about 90% of patients with secondary syphilis.[1]

Causes[edit]

The Jarisch–Herxheimer reaction is traditionally associated with antimicrobial treatment of syphilis.[2] The reaction is also seen in the other diseases caused by spirochetes: Lyme disease, relapsing fever, and leptospirosis.[3] There have been case reports of the Jarisch-Herxheimer reaction accompanying treatment of other infections, including Q fever, bartonellosis, brucellosis, trichinellosis, and African trypanosomiasis.[2]

Pathophysiology[edit]

Lipoproteins released from treatment of Treponema pallidum infections are believed to induce the Jarisch-Herxheimer reaction.[2] The Herxheimer reaction has shown an increase in inflammatory cytokines during the period of exacerbation, including tumor necrosis factor alpha, interleukin-6 and interleukin-8.[4][5]

Treatments[edit]

Prophylaxis and treatment with an anti-inflammatory agent may stop progression of the reaction. Oral aspirin or ibuprofen every four hours for a day or 60 mg of prednisone orally or intravenously has been used as an adjunctive treatment[citation needed]. However, steroids are generally of no benefit. Patients must be closely monitored for the potential complications (collapse and shock) and may require IV fluids to maintain adequate blood pressure. If available, meptazinol, an opioid analgesic of the mixed agonist/antagonist type, should be administered to reduce the severity of the reaction. Anti TNF-a may also be effective.[6][7]

History[edit]

Both Adolf Jarisch,[8] an Austrian dermatologist, and Karl Herxheimer,[9] a German dermatologist, are credited with the discovery of the Jarisch–Herxheimer reaction. Both Jarisch and Herxheimer observed reactions in patients with syphilis treated with mercury. The reaction was first seen following treatment in early and later stages of syphilis treated with Salvarsan, mercury, or antibiotics. Jarisch thought that the reaction was caused by a toxin released from the dying spirochetes.[10]

References[edit]

  1. ^ Lukehart, Sheila A. (2017). "Syphilis". In Kasper, Dennis L.; Fauci, Anthony S. Harrison's Infectious Diseases (3 ed.). New York: Mc Graw-Hill. p. 666. ISBN 978-1-259-83597-1. 
  2. ^ a b c Belum GR, Belum VR, Chaitanya Arudra SK, Reddy BS (2013). "The Jarisch-Herxheimer reaction: revisited". Travel Medicine and Infectious Disease. 11 (4): 231–7. PMID 23632012. doi:10.1016/j.tmaid.2013.04.001. 
  3. ^ Butler T (2017). "The Jarisch-Herxheimer Reaction After Antibiotic Treatment of Spirochetal Infections: A Review of Recent Cases and Our Understanding of Pathogenesis". The American Journal of Tropical Medicine and Hygiene. 96 (1): 46–52. PMID 28077740. doi:10.4269/ajtmh.16-0434. 
  4. ^ Vidal V, Scragg IG, Cutler SJ, et al. (December 1998). "Variable major lipoprotein is a principal TNF-inducing factor of louse-borne relapsing fever". Nat. Med. 4 (12): 1416–20. PMID 9846580. doi:10.1038/4007. 
  5. ^ Kaplanski G, Granel B, Vaz T, Durand JM (July 1998). "Jarisch–Herxheimer reaction complicating the treatment of chronic Q fever endocarditis: elevated TNFalpha and IL-6 serum levels". J. Infect. 37 (1): 83–4. PMID 9733392. doi:10.1016/S0163-4453(98)91120-3. 
  6. ^ Fekade, D; Knox, K; Hussein, K; Melka, A; Lalloo, DG; Coxon, RE; Warrell, DA (Aug 1, 1996). "Prevention of Jarisch–Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha.". The New England Journal of Medicine. 335 (5): 311–5. PMID 8663853. doi:10.1056/NEJM199608013350503. 
  7. ^ Coxon, RE; Fekade, D; Knox, K; Hussein, K; Melka, A; Daniel, A; Griffin, GG; Warrell, DA (Mar 1997). "The effect of antibody against TNF alpha on cytokine response in Jarisch–Herxheimer reactions of louse-borne relapsing fever." (PDF). QJM : Monthly Journal of the Association of Physicians. 90 (3): 213–21. PMID 9093599. doi:10.1093/qjmed/90.3.213. 
  8. ^ Jarisch A (1895). "Therapeutische Versuche bei Syphilis". Wien Med Wochenschr. 45: 721–42. 
  9. ^ Herxheimer K, Krause D (1902). "Ueber eine bei Syphilitischen vorkommende Quecksilberreaktion". Deutsch Med Wochenschr. 28 (50): 895–7. doi:10.1055/s-0028-1139096. 
  10. ^ "The Jarisch–Herxheimer reaction". Lancet. 1 (8007): 340–1. February 1977. PMID 64863. doi:10.1016/s0140-6736(77)91140-0. 

See also[edit]